Home > Neurology > EAN 2021 > Multiple Sclerosis and NMOSD > No higher early MS relapse frequency after stopping ponesimod

No higher early MS relapse frequency after stopping ponesimod

Presented by
Prof. Ludwig Kappos, University of Basel, Switzerland
Conference
EAN 2021
Trial
Phase 3, OPTIMUM
In a post-hoc analysis of the OPTIMUM study, short-term observational data in patients who stopped ponesimod for 6-168 days did not suggest a higher early relapse frequency than during treatment, or compared with teriflunomide. Furthermore, there was no clear pattern of disease reactivation, nor an indication that post-treatment relapses were usually severe or leading to persistent disability.

Ponesimod is an orally active, selective S1P1-receptor modulator that induces rapid, dose-dependent, and reversible reductions in peripheral blood lymphocyte count. In the phase 3 OPTIMUM study (NCT02425644), ponesimod 20 mg demonstrated superior efficacy versus teriflunomide 14 mg in reducing annualised relapse rate (ARR) in patients with relapsing MS [1]. Cases of exacerbation of MS activity have been reported after discontinuation of S1P1-receptor modulators.

Prof. Ludwig Kappos (University of Basel, Switzerland) reported on the post-treatment relapse activity in the OPTIMUM study [2]. He explained that all patients who completed treatment in the OPTIMUM study after 108 weeks, regardless of treatment group, interrupted treatment for at least 2 weeks and, for teriflunomide, underwent an accelerated elimination procedure. All patients who stopped treatment, either prematurely or not, entered safety follow-up (at least 30 days after the last dose), and a post-treatment observation period (from the last dose up to 108 weeks after randomisation).

Of 1,133 randomised patients, 1,124 had post-treatment observation. In the ponesimod and teriflunomide group, 88 and 92 patients stopped treatment prematurely, respectively. Eight patients in the ponesimod group and 14 in the teriflunomide group experienced a total of 23 post-treatment relapses within 182 days of the last received dose of either study drug. Post-treatment ARR did not exceed on-treatment ARR for both drugs. Including non-confirmed relapses, ARR in the ponesimod group was 0.246 on-treatment, and 0.186 off-treatment; ARR in the teriflunomide group was 0.348 and 0.294, respectively. These findings are consistent with the main OPTIMUM results up to the end of the study. There were 8 confirmed on-treatment relapses in 5 ponesimod-treated patients, and 9 relapses (3 confirmed) in 8 patients between 6 and 168 days post-treatment, without any pattern of latency or severity.

  1. Kappos L, et al. JAMA Neurol. 2021 May 1;78(5):558-67.
  2. Kappos L, et al. Analysis of post-treatment relapse activity in the phase 3 OPTIMUM study of ponesimod compared with teriflunomide. OPR-208, EAN 2021 Virtual Congress, 19–22 June.

 

Copyright ©2021 Medicom Medical Publishers



Posted on